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Abstract
Childhood maltreatment (CM) has been associated with altered brain morphology, which may partly be due to a direct
impact on neural growth, e.g. through the brain-derived neurotrophic factor (BDNF) pathway. Findings on CM, BDNF and
brain volume are inconsistent and have never accounted for the entire BDNF pathway. We examined the effects of CM,
BDNF (genotype, gene expression and protein level) and their interactions on hippocampus, amygdala and anterior cingu-
late cortex (ACC) morphology. Data were collected from patients with depression and/or an anxiety disorder and healthy
subjects within the Netherlands Study of Depression and Anxiety (NESDA) (N¼289). CM was assessed using the Childhood
Trauma Interview. BDNF Val66Met genotype, gene expression and serum protein levels were determined in blood and T1
MRI scans were acquired at 3T. Regional brain morphology was assessed using FreeSurfer. Covariate-adjusted linear regres-
sion analyses were performed. Amygdala volume was lower in maltreated individuals. This was more pronounced in mal-
treated met-allele carriers. The expected positive relationship between BDNF gene expression and volume of the amygdala
is attenuated in maltreated subjects. Finally, decreased cortical thickness of the ACC was identified in maltreated subjects
with the val/val genotype. CM was associated with altered brain morphology, partly in interaction with multiple levels of
the BNDF pathway. Our results suggest that CM has different effects on brain morphology in met-carriers and val-
homozygotes and that CM may disrupt the neuroprotective effect of BDNF.
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Introduction
Childhood maltreatment (CM), which comprises neglect and
psychological, physical and sexual abuse, can lead to a wide
range of adverse consequences. CM is associated with the de-
velopment of various psychiatric disorders, including major de-
pressive disorder, post-traumatic stress disorder and addiction
(Molnar et al., 2001; Spinhoven et al., 2010), and has been
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associated with an unfavorable disease course and poor re-
sponse to treatment (Hovens et al., 2012; Nanni et al., 2012). CM
has also been associated with changes in regional brain morph-
ology: decreased volume of the hippocampus (Dannlowski et al.,
2012; Teicher et al., 2012; Hanson et al., 2014), amygdala (Hanson
et al., 2014) and prefrontal cortex (Dannlowski et al., 2012; Van
Harmelen et al., 2010) have been reported in individuals with a
history of CM, although results regarding hippocampal and
amygdala volume have been inconsistent (Van Harmelen et al.,
2010; Dannlowski et al., 2012).
These inconsistent findings regarding the impact of CM on
brain morphology could perhaps be explained by postulating
that the effect of environmental stress is more prominent in in-
dividuals with a biological vulnerability. Previous studies have
provided some evidence for an interaction effect of childhood
maltreatment and a specific genotype of the brain-derived
neurotrophic factor (BDNF) gene on regional brain volume.
BDNF is a protein that is important for plasticity, neurogenesis
and neuronal survival (Huang and Reichardt, 2001). The met-
allele of the Val66Met Single-Nucleotide Polymorphism (SNP) of
the BDNF gene, coding for a replacement of the amino acid val-
ine (val) by methionine (met), has been associated with
decreased activity-dependent secretion of BDNF (Egan et al.,
2003; Chen et al., 2004). Previous studies investigating a BDNF
gene by CM interaction have shown that Met-carriers of the
BDNF gene with a history of CM have decreased volume of the
anterior cingulate cortex (ACC) (Gerritsen et al., 2012), hippo-
campus (Molendijk et al., 2012; Carballedo et al., 2013; Frodl et al.,
2014) and amygdala (Gatt et al., 2009) compared to met-carriers
without CM and individuals with a val/val genotype, although
again results have been inconsistent (Gerritsen et al., 2012).
The above mentioned studies focused on the Val66Met geno-
type. However, Val66Met genotype is only one element of the
BDNF pathway. Previous studies have not examined other elem-
ents of the BDNF pathway including BDNF gene expression lev-
els and serum protein levels. Therefore, in the current study, we
examined the effect of CM and different markers in the BDNF
pathway, and the interaction between CM and BDNF on volume
of the hippocampus and amygdala and cortical thickness and
surface area of the ACC. We expected an overall negative effect
of CM on regional brain morphology. Consistent with previous
studies, we hypothesized a gene-environment interaction effect
showing a stronger decrease in amygdala and hippocampus
volume and ACC thickness and surface area in met-carriers
with a history of CM. Due to the important role of BDNF in neur-
onal survival, we expected a positive relationship between
BDNF protein and gene expression levels and regional brain vol-
ume and cortical measures. To our knowledge, no previous
studies have examined the relationship between BDNF gene ex-
pression or BDNF protein levels and brain morphology in rela-
tion to CM, but we expected that stress may obscure the
protective effect of BDNF gene expression or serum levels on re-
gional brain morphology in maltreated subjects.
Materials and methods
Subjects
The Netherlands Study of Depression and Anxiety (NESDA) is a
longitudinal cohort study, which aims to examine the naturalis-
tic course of depression and anxiety in a total of 2981 partici-
pants. NESDA includes subjects with depressive and/or anxiety
disorder as well as subjects without a lifetime psychiatric diag-
nosis. Subjects were recruited from the community, general
practitioners and specialized mental health care institutions
(for details please see Penninx et al., 2009).
A subgroup of NESDA patients and healthy controls were
asked to participate in the NESDA neuroimaging study (N¼ 301).
Inclusion criteria for the imaging study were a DSM-IV diagnosis
of major depressive disorder (MDD) and/or anxiety disorder (so-
cial anxiety disorder and/or panic disorder and/or generalized
anxiety disorder) in the six months preceding the interview for
patients and no history of psychiatric disorders for controls.
These diagnoses were established using the Composite
International Diagnostic Interview (CIDI version 2.1) (Wittchen,
1994). Exclusion criteria for patients and controls were abuse or
dependency of drugs or alcohol in the past year, general MRI
contraindications and presence or history of a severe internal or
neurological disorder. Additional exclusion criteria were use of
psychotropic medication other than stable use of SSRIs or infre-
quent benzodiazepine use for patients and use of any psycho-
active medication for healthy controls. The Ethical Review
Boards of the three participating centers (i.e. Academic Medical
Center Amsterdam, University Medical Center Groningen and
Leiden University Medical Center) approved this study and all
subjects provided written consent.
In the current study we included all healthy controls and pa-
tients with a 6-month diagnosis of MDD and/or an anxiety dis-
order. We excluded twelve participants due to poor image
quality, leaving a total of 289 subjects in our study.
Maltreatment
Childhood maltreatment was assessed with the Nemesis
Childhood Trauma Interview (De Graaf et al., 2002). In this semi-
structured interview, participants were asked whether they had
ever experienced emotional neglect, psychological abuse, phys-
ical abuse or sexual abuse before the age of 16 (see supplements
for a detailed description). As these forms of abuse often occur
together (Hovens et al., 2010), it is difficult to examine effects
related to specific forms of maltreatment. Therefore, we used a
broad definition of CM and classified subjects as having a his-
tory of childhood abuse if they reported at least one type of
maltreatment.
Imaging
Imaging was performed on 3T Philips MR scanners (Philips,
Best, The Netherlands) at the three participating centers (Leiden
University Medical Center, Amsterdam Medical Center and
University Medical Center Groningen). In Amsterdam, a SENSE-
6 channel head coil was used, while the other sites used a
SENSE-8 channel head coil. Anatomical scans were acquired
using a sagittal three-dimensional gradient-echo T1-weighted
sequence (TR: 9 ms; TE: 3.5 ms; matrix: 256_256; voxel size:
1 mm3; 170 slices)
Cortical reconstruction and volumetric segmentation were
performed using FreeSurfer image analysis suite (version 5.3;
Martinos Center for Biomedical Imaging, Harvard-MIT, Boston,
MA; http://surfer.nmr.mgh.harvard.edu/). FreeSurfer includes
motion correction and averaging, Talairach transformation, re-
moval of non-brain tissue, segmentation of subcortical struc-
tures and cortical regions, intensity normalization and cortical
reconstruction. For quality assessment, a visual inspection of
all subcortical structures and cortical regions was performed,
using a protocol developed by the ENIGMA consortium (http://
enigma.ini.usc.edu/protocols/imaging-protocols/).
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We chose volumes of the amygdala and hippocampus and
cortical thickness and surface area of the rostral and caudal
ACC as regions of interest in the current study, because of their
specific association with both CM and BDNF (Gatt et al., 2009;
Gerritsen et al., 2012; Frodl et al., 2014).
Brain-derived neurotrophic factor (BDNF)
Val66met genotype. Methods for biological sample collection
and DNA extraction have been described previously (Boomsma
et al., 2008; Abdellaoui et al., 2013). In brief, genotyping was per-
formed on multiple chip platforms in different, and partially
overlapping subsets of the total NESDA sample (Affymetrix-
Perlegen 5.0 and Affymetrix 6.0). Quality checks and imputation
methods have been detailed in a previous report and are
described in the supplement (Nivard et al., 2014). In subsequent
analyses, we compared subjects who had at least one met-allele
to val-val homozygotes (dominant model).
Gene expression measurement. RNA processing and measure-
ments have likewise been outlined previously (Jansen et al.,
2014) and are described in the supplement. In this study, we cal-
culated the mean BDNF expression across all five probe sets
after correcting for technical covariates (i.e. plate number, pos-
ition on plate, month and hour of blood withdrawal, hemoglo-
bin level and days between blood withdrawal and RNA
extraction).
Serum protein measurement. Blood withdrawal was performed
in the morning between 7:30 and 9:30 after subjects had fasted
overnight. Serum was extracted and stored at85 C. Protein
levels were measured using the Emax ImmunoAssay system
from Promega (for this procedure, see Bus et al., 2011). All serum
BDNF protein levels (expressed in nanograms per milliliter)
were above the reliable detection limit of the ELISA kit (1.56 ng/
ml).
Statistical analyses
Sample characteristics. To examine differences in demographi-
cal variables, BDNF measures and brain structure between indi-
viduals who had and those who had not experienced CM, we
used independent sample t-tests and v2 tests. We considered all
results significant if P < 05.
BDNF correlations. Partial correlation coefficients were calcu-
lated to examine the relationship between BDNF gene expres-
sion and BDNF serum levels, while correcting for age, sex and
education level. Point-biserial correlation coefficients were cal-
culated with similar covariates to investigate the association
between BDNF Val66Met genotype and gene expression levels
and between Val66Met genotype and serum protein levels.
Repeated measures ANOVA analyses. For our primary analyses,
we performed repeated measures ANOVA analyses in SPSS 20
(IBM) to examine the main effects of CM on subcortical brain
volume and cortical thickness. Furthermore, main effects of
BDNF Val66Met (dummy coded 0 for met-carriers and 1 for val-
allele homozygotes), gene expression levels and BDNF serum
protein levels on brain morphology were explored. In addition,
repeated measure ANOVA analyses were performed to examine
the interaction of CM with Val66Met genotype, BDNF gene ex-
pression levels and serum protein levels on brain morphology
in different models for each BDNF marker. Hemisphere (left or
right) was added to the model as a within-group factor to inves-
tigate whether there were significant two-way
(BDNF*hemisphere or CM*hemsiphere) or three-way
(BDNF*CM*hemisphere) lateralization effects. If a significant
interaction was observed, post-hoc tests were performed to
examine by which hemisphere the results were driven.
Significant interactions were followed by two-sample t-tests
(Bonferroni corrected for the number of post-hoc comparisons)
or stratified regression analyses to examine group differences.
In secondary analyses, potential confounding effects of SSRI
use, smoking, alcohol use and population structure were con-
trolled for by performing linear regression analyses with these
variables as additional covariates (see below).
Covariates. Potential variance due to age, sex, education level
(in years), scan site, presence of depression (coded as a dummy
variable: yes/no), presence of an anxiety disorder (coded as a
dummy variable: yes/no) and intracranial volume was corrected
for all regression and ANOVA analyses. In secondary analyses
we also corrected for smoking (coded as a dummy variable: cur-
rent smoker vs non-smoker), alcohol use (number of alcohol
drinks per week) and SSRI use (coded as a dummy variable: yes/
no). Analyses focusing on Val66Met SNP were additionally ad-
justed for three ancestry-informative principal components
derived from GWAS data (Abdellaoui et al., 2013) to take possible
population stratification into account.
Effect of psychiatric diagnosis
As maltreatment, depression and anxiety disorders are strongly
associated and we examine the effect of maltreatment in a sam-
ple that includes patients with depression and/or anxiety dis-
orders, we performed additional analyses to examine if
presence of a psychiatric disorder has a similar effect as CM on
brain morphology. Presence of a psychiatric diagnosis (coded as
a dummy: yes/no) was entered into repeated measure ANOVA
analyses with age, sex, education, scan site and intracranial vol-
ume added as covariates.
Results
Sample characteristics
Table 1 shows the demographic and biological characteristics of
our total sample (N¼ 289) and stratified for CM. Subjects with a
history of CM (N¼ 146) had smaller amygdala volumes
(P¼ 0.017) and more often had a diagnosis of depressive and/or
anxiety disorders (both P< 0.01) than subjects who were not
maltreated (N¼ 143). Age, sex, education level, total intracranial
volume, Val66Met genotype, BDNF gene expression levels and
serum protein levels did not differ between maltreated and
non-maltreated subjects.
Due to missing BDNF values, 255 subjects were included in
Val66Met genotype analyses, 195 subjects in BDNF gene expres-
sion analyses and 282 subjects in BDNF protein analyses.
Childhood maltreatment and brain morphology
In covariate adjusted repeated measures ANOVA analyses, pres-
ence of CM was associated with decreased volume of the amyg-
dala (P¼ 0.038) (Table 2). CM was unrelated to hippocampal
volume or ACC thickness and surface area. There was no signifi-
cant interaction between CM and hemisphere on brain morph-
ology (Table S1), indicating that findings were not driven by one
hemisphere.
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BDNF and brain morphology
BDNF Val66Met, gene expression levels or serum protein levels
were not associated with volume of the amygdala and hippo-
campus or ACC morphology (Table 2). However, at a trend level,
there was an association between BDNF Val66Met genotype and
surface area of the caudal ACC (P¼ 0.060), with increased sur-
face area observed in met-carriers (M:773.81; SD:123.44) com-
pared to individuals with a val/val genotype (M:742.91;
SD:133.45). There was also a trend for a positive association be-
tween BDNF gene expression levels and amygdala volume
(P¼ 0.082). The above mentioned findings were not driven by
one hemisphere as there were no significant BDNF*hemisphere
interaction effects (Table S1).
Interaction between maltreatment and BDNF
Interaction between maltreatment and Val66Met. We observed
an interaction effect between CM and Val66Met genotype on
amygdala volume (P< 0.001; Table 2 and Figure 1). Post-hoc
ANCOVA tests indicated that in individuals with a history of
CM, the met-allele was associated with decreased amygdala
volume (M: 1555.23; SE: 25.00), compared to non-maltreated
met-carriers (M: 1704.94; SE: 24.94) (P¼ 0.003, Bonferroni-
corrected). There was no significant CM*Val66Met*hemisphere
interaction effect (P¼ 0.099; Table S1), suggesting that this find-
ing was not driven by one hemisphere.
We also observed an interaction effect between CM and
Val66Met on thickness of the caudal and rostral ACC (Figure 1;
P¼ 0.007 and P¼ 0.029, respectively). Post-hoc tests did not
show significant differences between groups in caudal ACC
thickness, but rostral ACC thickness was lower in maltreated in-
dividuals with a val/val genotype (M: 2.547; SE:0.013), compared
to non-maltreated individuals with a val/val genotype (M:2.593;
SE:0.017) (P¼ 0.051, Bonferroni-corrected). This CM*Val66Met
interaction effect appeared to be driven by the right hemisphere
ACC (post-hoc regression analysis: standardized beta: 0.322;
SE: 0.119; T¼2.707, P¼ 0.007) and not the left hemisphere ACC
(standardized beta: 0.062; SE: 0.113 T¼0.547, P¼ 0.585), as
there was a significant three-way interaction between CM,
Val66Met genotype and hemisphere on rostral ACC thickness
(Table S1).
Hippocampal volume and ACC surface area were not associ-
ated with an interaction between CM and Val66Met genotype
(Table 2).
Interaction between maltreatment and BDNF gene expression.
A significant interaction effect between CM and BDNF gene ex-
pression levels on amygdala volume was observed (P¼ 0.010;
Table 2 and Figure 2). Post-hoc regression analyses stratified for
Table 1. Sample characteristics and differences between maltreated and non-maltreated subjects








T/F/X2 (df) P-value Cohen’s D
Demographic variables
Age (years; s.d.) 37.69 (10.16) 38.43 (9.70) 36.92 (10.59) T¼1.263 (287) 0.208 0.149
Sex (female/male)(% male) 32.9% 32.2% 32.9% X2 ¼ 0.000 (1) 1.00 0.000
Education (years; s.d.) 12.81 (3.20) 12.60 (3.29) 13.02 (3.09) T ¼ 1.113 (287) 0.267 0.132
Scan site (Amsterdam/
Leiden/Groningen)
94/107/88 49/53/44 45/54/44 X2 ¼ 0.148 (2) 0.928 0.045
Brain morphology
ICV (liter; s.d.) 1.5081 (0.183) 1.5079 (0.176) 1.5084 (0.190) F ¼ 0.060 (1) 0.807e 0.002
Mean amygdala volume (mm3; s.d) 1637.34 (201.29) 1609.31 (209.46) 1665.97 (189.05) F ¼ 5.722 (1) 0.017f 0.284
Mean hippocampal volume (mm3; s.d.) 3989.63 (423.48) 3965.69 (418.80) 4014.07 (428.29) F ¼ 0.849 (1) 0.358f 0.114
Mean thickness rostral ACC (mm; s.d.) 2.57 (0.16) 2.55 (0.17) 2.59 (0.15) F ¼ 2.765 (1) 0.097f 0.250
Mean thickness caudal ACC (mm; s.d.) 2.39 (0.18) 2.38 (0.17) 2.41 (0.18) F ¼ 0.924 (1) 0.337f 0.171
Surface area rostral ACC (mm; s.d.) 805.60 (131.75) 808.24 (135.98) 802.92 (127.73) F ¼ 0.326 (1) 0.568f 0.040
Surface area caudal ACC (mm; s.d.) 755.92 (129.65) 748.47 (122.57) 763.48 (136.46) F ¼ 1.326 (1) 0.251f 0.116
Brain-derived neurotrophic factor
Genotype (% met carriers)a 33.6% 32.2% 35.0% X2 ¼ 0.400 (1) 0.527 0.074
Gene expressionb 2.19 (0.12) 2.18 (0.11) 2.19 (0.13) F ¼ 0.799 (1) 0.373g 0.083
Serum protein levels (ng/ml)c 8.99 (3.12) 9.08 (3.03) 8.90 (3.22) F ¼ 0.069 (1) 0.793g 0.058
Psychiatry and lifestyle
Depression (%)d 54.0% 63.7% 44.1% X2 ¼ 11.221 (1) 0.001 0.402
Anxiety disorder (%)d 55.7% 65.1% 46.2% X2 ¼ 10.475 (1) 0.001 0.388
Smoking (% yes) 33.6% 33.2% 35.0% X2 ¼ 0.249 (1) 0.618 0.058
SSRI use (% yes) 27.3% 31.5% 23.1% X2 ¼ 2.585 (1) 0.108 0.190
Alcohol use (drinks per week) 5.14 (7.79) 4.63 (8.39) 5.68 (7.12) T ¼ 1.143 (286) 0.254 0.135
Data are shown as mean (standard deviation) or as frequencies.
ACC: anterior cingulate cortex; ICV: intracranial volume; s.d.: standard deviation.
aDue to missing values genotype data was available for 255 subjects, of which 130 had a history of maltreatment.
bDue to missing values gene expression data was available for 195 subjects, of which 107 had a history of maltreatment.
cDue to missing values protein serum levels was available for 282 subjects, of which 143 had a history of maltreatment.
dPresence of an anxiety and/or depressive disorder.
eCorrected for age, sex, education level, scan site.
fCorrected for age, sex, education level, scan site, intracranial volume.
gCorrected for age, sex, education level.
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CM revealed that BDNF gene expression was positively associ-
ated with amygdala volume in individuals without CM (standar-
dized beta: 0.252 SE: 0.094; T¼ 2.687; P¼ 0.009), while this
relationship was absent in individuals with a history of CM
(standardized beta: -0.066; SE: 0.091;T¼0.722; P¼ 0.472).
There was also a significant interaction between BDNF gene
expression and CM on rostral ACC thickness (P¼ 0.029; Table 2
and Figure 2). Stratified post-hoc analysis revealed a trendwise
positive relationship between gene expression and thickness in
individuals without CM (standardized beta: 0.190; SE: 0.102;
T¼ 1.869; P¼ 0.065) and a negative, but non-significant relation-
ship in individuals with a history of CM (standardized beta:
0.125; SE: 0.096; T¼1.297; P¼ 0.198).
Hippocampal volume and caudal ACC thickness were unre-
lated to an interaction between CM and BDNF expression. In
addition, no significant CM*gene expression*hemisphere inter-
action effects were observed (Table S1).
Interaction between maltreatment and BDNF serum protein
levels. We did not observe an interaction effect between BDNF
protein levels and CM on amygdala and hippocampus volumes
or ACC cortical thickness and surface area (Table 2).
Psychiatric diagnosis, BDNF and brain volume
While depression and anxiety disorders were corrected for in all
analyses, we performed additional analyses to examine to what
extent our findings could also be explained by psychiatric sta-
tus. Presence of a psychiatric disorder was associated with
decreased volume of the hippocampus, rostral ACC thickness
and caudal ACC surface area (P¼ 0.029, P < 0.001 and P¼ 0.008,
respectively; Table 3) and amygdala volume and caudal ACC
thickness at trend-level (P¼ 0.064 and P¼ 0.059, respectively,
Table 3). We also observed an interaction between psychiatric
diagnosis and Val66Met genotype on thickness of the rostral
ACC and surface area of the caudal ACC (P¼ 0.051 and 0.007;
Table 3). Post-hoc ANCOVA analyses did not reveal significant
differences in rostral ACC thickness between groups, but did re-
veal a trend towards decreased caudal ACC surface area in pa-
tients with val/val genotype (M 738.62; SD: 128.53) compared to
healthy met-carriers (M: 819.95; SD: 141.79) (P¼ 0.058;
Bonferroni-corrected). These results suggest that the CM*BDNF
genotype effect on the ACC may be partly explained by a
psychiatry*BDNF interaction effect.
Furthermore, there was an interaction effect between psychi-
atric diagnosis and BDNF gene expression levels on thickness of
the rostral ACC (P < 0.001; Table 3). Stratified analyses showed
that there was a positive effect of BDNF gene expression on ros-
tral ACC thickness in healthy controls (standardized beta: 0.510;
SE: 0.172; T¼2.972; P¼ 0.006), which was absent in patients
(standardized beta:0.141; SE: 0.075; T¼1.888; P¼ 0.061).
There was no interaction effect of psychiatric diagnosis and
BDNF on amygdala volume, suggesting that the observed inter-
action effects of CM, Val66Met genotype and BDNF gene expression
levels on amygdala volume are independent of psychiatric status.
Secondary analyses
Correction for additional confounding variables. Results of the
secondary analyses correcting for potential confounders
Table 2. Main effects and interaction effects of childhood maltreatment and BDNF on brain morphology measures
Regions of interest Childhood maltreatment N ¼ 289 BDNF genotype N ¼ 255 Childhood maltreatment x genotype
interaction N ¼ 255
Df F P-value Partial g2 Df F p-value Partial g2 Df F P-value Partial g2
Hippocampus 1,279 0.330 0.566 0.001 1,242 0.018 0.894 0.000 1,240 1.908 0.168 0.008
Amygdala 1,279 4.334 0.038 0.015 1,242 0.124 0.725 0.001 1,240 21.588 0.000 0.083
Th. caudal ACC 1,279 0.091 0.763 0.000 1,242 0.264 0.608 0.001 1,240 7.315 0.007 0.030
Th. rostral ACC 1,279 0.894 0.345 0.003 1,242 0.762 0.384 0.003 1,240 4.822 0.029 0.020
SA caudal ACC 1,278 0.317 0.574 0.001 1,241 3.578 0.060 0.015 1,240 1.033 0.310 0.004
SA rostral ACC 1,278 1.010 0.316 0.004 1,241 2.209 0.138 0.009 1,240 0.190 0.663 0.001
BDNF gene expression N¼ 195 Childhood maltreatment x expression
interaction N ¼ 195
Df F p-value Partial g2 Df F p-value Partial g2
Hippocampus 1,185 0.990 0.321 0.005 1,183 0.649 0.422 0.004
Amygdala 1,185 3.062 0.082 0.016 1,183 6.838 0.010 0.036
Th, caudal ACC 1,185 0.211 0.646 0.001 1,183 0.679 0.411 0.004
Th. rostral ACC 1,185 0.018 0.894 0.000 1,183 4.826 0.029 0.026
SA caudal ACC 1,184 0.379 0.539 0.002 1,182 0.908 0.342 0.005
SA rostral ACC 1,184 0.373 0.542 0.002 1,182 0.052 0.819 0.000
BDNF protein levels N¼ 282 Childhood maltreatment x protein
interaction N¼ 282
Df F p-value Partial g2 Df F p-value Partial g2
Hippocampus 1,272 1.715 0.191 0.006 1,270 0.811 0.368 0.003
Amygdala 1,272 0.080 0.777 0.000 1,270 0.390 0.533 0.001
Th. caudal ACC 1,272 0.036 0.849 0.000 1,270 1.097 0.296 0.004
Th. rostral ACC 1,272 0.043 0.835 0.000 1,270 0.052 0.819 0.000
SA caudal ACC 1,271 0.226 0.635 0.001 1,269 2.345 0.127 0.009
SA rostral ACC 1,271 0.755 0.386 0.003 1,269 1.818 0.179 0.007
Results of repeated measure ANOVA analyses. The dependent variables (hippocampal and amygdala volume, cortical thickness and surface area of the ACC) are shown
in the first column. Presented results are corrected for differences in age, sex, educational level, diagnosis of depression and diagnosis of anxiety, scan site and intra-
cranial volume. ACC: anterior cingulate cortex; SA: surface area Th.:cortical thickness.
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(i.e. SSRI use, smoking and alcohol use) are presented in table
S2. Following this additional correction, we still observed a
main effect of CM on amygdala volume (P¼ 0.030). The inter-
action effects of CM and Val66Met on amygdala volume and
thickness of the caudal and rostral ACC remained significant
(P< 0.001, P¼ 0.007 and P¼ 0.022, respectively). Furthermore, the
interaction effects between CM and BDNF gene expression on
amygdala volume and rostral ACC thickness also remained sig-
nificant (P¼ 0.005 and P¼ 0.033).
Correlation between Val66Met, BDNF gene expression and
amygdala volume. Since we observed both a significant inter-
action effect between CM*Val66Met and between CM* BDNF
gene expression levels on amygdala volume, we additionally
examined whether these two interaction effects related to each
other. To this aim we performed an additional post-hoc linear
regression analysis in which we included these variables, cova-
riates, as well as both interaction terms with amygdala volume
as outcome. Both interaction terms remained significant
(CM*gene expression: standardized beta¼0.228; SE¼ 0.084;
T¼2.703; P¼ 0.008; CM*gene: standardized beta¼ 0.431;
SE¼0.121; T¼ 3.571; P< 0.001), indicating that the observed
interaction effects were independent from each other. This in-
dependence between BDNF genotype and gene expression is
further demonstrated by a lack of association between the dif-
ferent BDNF markers. The correlation between BDNF gene ex-
pression levels and protein levels was not significant (R¼0.041,
P¼ 0.582). There was no significant correlation between
Val66Met genotype and gene expression levels (Rpb¼0.05;
P¼ 0.5) and between Val66Met genotype and protein levels.
(Rpb¼0.01; P¼ 0.869).
Discussion
The aim of this study was to examine the effect of CM, BDNF
and their interaction on volume of the amygdala and hippo-
campus and thickness of the ACC. This is the first study to
examine multiple levels of the BDNF pathway—including the
Val66Met SNP, gene expression and protein levels—in relation
to CM. Amygdala volume was lower in subjects with a history of
CM. Furthermore, we found a gene-environment interaction on
amygdala volume and thickness of the ACC. We also observed
these interaction effects at the gene expression level.
Overall, amygdala volume was lower in subjects who were
exposed to CM. The amygdala is a key structure for processing
emotional information including memory formation and has
been implicated in many maltreatment-related disorders,
including post-traumatic stress disorder and other anxiety dis-
orders (Etkin and Wager, 2007). Previous studies have reported
conflicting results, including increased (Pechtel et al., 2014),
decreased (Edmiston et al., 2011; Hanson et al., 2014) and un-
altered amygdala volume (Woon and Hedges, 2008) in mal-
treated subjects. Rodent studies have shown an increase in
dendritic arborisation in the amygdala in response to stress
(Vyas et al., 2002; Padival et al., 2013), which may result in an in-
crease in volume. It has been proposed that CM may cause an
initial increase in amygdala volume and activity, which over
time may be followed by neurodegeneration and reduced vol-
ume of the amygdala in maltreated subjects (Hanson et al.,
2014). In support of this hypothesis, prolonged stress was asso-
ciated with degeneration of amygdala cells in adult rats (Ding
et al., 2010). Our finding of lower amygdala volume in mal-
treated adults also fits this model, although longitudinal re-
search is needed to corroborate our results. Given the role of the
amygdala in emotion processing, we speculate that decreased
amygdala volume may underlie emotion regulation impair-
ments in maltreated subjects (Dvir et al., 2014; O’Mahen et al.,
2015).
We did not find evidence for a direct effect of BDNF on brain
morphology. As BDNF is expressed in the prefrontal cortex,
amygdala and hippocampus (Conner et al., 1997; Dwivedi et al.,
2003), and is crucial for neurogenesis and neuronal survival
(Huang and Reichardt, 2001), we expected a positive relation-
ship between BDNF (gene expression levels and serum protein
Fig. 1. BDNF Val66Met genotype and brain morphology in maltreated and
non-maltreated subjects. (A) An interaction effect between Val66Met and
childhood maltreatment on amygdala volume. Post-hoc t-tests were performed.
*:significant at P < 0.05 (Bonferroni-corrected). (B) Interaction effect
between Val66Met and childhood maltreatment on thickness of the caudal ACC.
Post-hoc tests do not show significant differences between groups. (C) An inter-
action effect between Val66Met and childhood maltreatment on thickness of
the rostral anterior cingulate cortex. Post-hoc t-tests were performed *: signifi-
cant at P<0.05 (Bonferroni-corrected). All presented results are corrected for dif-
ferences in age, gender, educational level, scan site and intracranial volume.
Error bars indicate the standard error of the mean. ACC: anterior cingulate cor-
tex; CM-: no history of childhood maltreatment; CMþ: history of childhood
maltreatment.
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levels) and measures of regional brain morphology. Previous
work has shown a positive relationship between serum protein
levels, hippocampal volume and memory performance
(Erickson et al., 2010), however this finding was not replicated in
later studies (Driscoll et al., 2012; Kim et al., 2015). In the current
study, the evidence for an effect of BDNF gene expression or
serum protein levels on brain morphology was limited. The ef-
fect of BDNF on brain volume may be small or BDNF levels may
vary over time, preventing us from detecting an effect of current
BDNF levels on volume of the amygdala, hippocampus and ACC
(Piccinni et al., 2008). We also did not see an effect of BDNF geno-
type on brain volume and therefore were unable to replicate ini-
tial findings of decreased hippocampus volume in carriers of
the met-allele (Bueller et al., 2006; M L Molendijk et al., 2012),
however recent meta-analyses suggest this effect is non-
existent and is related to publication bias (Marc L Molendijk
et al., 2012; Harrisberger et al., 2014).
Results of our interaction analyses suggest that smaller
amygdala volumes in individuals with a history of CM are even
more prominent in carriers of the met-allele of the BDNF gene.
The met-allele may increase vulnerability to CM related mor-
phological changes in the amygdala due to decreased activity-
dependent secretion of BDNF (Egan et al., 2003) or increased
HPA-axis reactivity to stress (Colzato et al., 2011; Yu et al., 2012)
in met-carriers. The amygdala has many glucocorticoid recep-
tors (Wang et al., 2013) and high glucocorticoid levels have been
associated with decreased amygdala volume (Schuhmacher
et al., 2012). Therefore increased glucocorticoid levels in re-
sponse to stress during development may result in decreased
amygdala volume in met carriers. A history of maltreatment
and the presence of a met-allele appear to interact to lead to
more pronounced reduced volume in maltreated met-carriers.
We did not find evidence for a similar interaction between de-
pression and/or anxiety and Val66Met genotype on amygdala
volume, suggesting that the interaction effects on amygdala
volume may not be related to depression and/or anxiety. It is
important to note that this is a cross-sectional study and that
longitudinal studies are needed to address any association
Fig. 2. BDNF gene expression and brain morphology in maltreated and non-maltreated subjects. Shown here are results of a stratified linear regression analysis.
(A) Interaction effect between BDNF gene expression and childhood maltreatment on amygdala volume. There is a positive relationship between BDNF gene expres-
sion and volume of the amygdala in subjects without a history of maltreatment, which is absent in maltreated subjects. (B) Interaction effect between BDNF gene ex-
pression and childhood maltreatment on rostral ACC thickness. Stratified analyses reveal a positive, but non-significant relationship in non-maltreated subjects and a
negative, but non-significant relationship in maltreated subjects. CM: no history of childhood maltreatment; CMþ: history of childhood maltreatment.
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between maltreatment—related changes in brain morphology
and development of maltreatment related psychiatric
disorders.
Although BDNF gene expression levels were not significantly
lower in maltreated subjects, alterations in the interaction be-
tween BDNF gene expression and CM on volume of the amyg-
dala were observed. In line of what would be expected, higher
levels of gene expression were associated with greater amyg-
dala volume and ACC thickness in non-maltreated individuals,
but this effect was absent in maltreated subjects. This lack of an
association between BDNF gene expression levels and amygdala
volume could be suggestive of an absence of a neuroprotective
effect of BDNF in maltreated subjects. This disruption could in
turn be explained by disrupted BDNF signalling downstream of
the receptor. For instance, pro-inflammatory cytokines and
glucocorticoids have been shown to interact and affect BDNF
signaling (see review by Numakawa et al., 2014). It has been re-
ported that BDNF-stimulated signaling in the AKT and ERK
pathways and BDNF-related facilitation of long term potenti-
ation (LTP) in the hippocampus is reduced after administration
of pro-inflammatory cytokine interleukin 1b (Tong et al., 2008;
Tong et al., 2012). Glucocorticoids have also been found to sup-
press BDNF signaling in the MAPK/ERK pathway (Kumamaru
et al., 2011). Increased levels of pro-inflammatory cytokines and
dysregulation of the HPA-axis have been observed in maltreated
individuals (Gonzalez, 2013; Coelho et al., 2014). High levels of
glucocorticoids and pro-inflammatory cytokines may thus
interfere with the effects downstream of the BDNF receptor in
maltreated individuals thereby interfering with the
neuroprotective effect of BDNF, yielding an absence of a positive
association between BDNF gene expression levels and amygdala
volume.
Our results suggest that the observed CM-Val66Met genotype
and CM-BDNF gene expression interaction effects on amygdala
morphology are independent, indicating that the effect of the
Val66Met gene on amygdala volume is not explained by BDNF
gene expression effects on amygdala volume in maltreated par-
ticipants. This is in line with our observation of a lack of an cor-
relation between the different markers. This is also in
accordance with previous studies, which did not find a differ-
ence in plasma BDNF levels between met-carriers and val/val
homozygotes (Terracciano et al., 2013; Chen et al., 2015). Perhaps
a one-to-one mapping of genotype to gene expression and
serum protein effects is also not to be expected because BDNF
serum protein and gene expression levels are influenced by
multiple genes, epigenetic effects and other biological markers,
including cytokines, glucocorticoids and sex hormones
(Carbone and Handa, 2013; Terracciano et al., 2013; Calabrese
et al., 2014), which may obscure the direct associations between
markers of BDNF.
The CM*BDNF interaction effects we observed are complex,
as maltreatment was related to decreased amygdala volume in
met-carriers and reduced cortical thickness of the right rostral
ACC in val-homozygotes. The rostral anterior cingulate is im-
portant for emotion regulation and is highly interconnected
with the amygdala (Etkin et al., 2011). Stress has been associated
with decreased dendritic arborisation in the anterior cingulate
cortex (Radley et al., 2004; Liston et al., 2006), which may
Table 3. Main effects and interaction effects of psychiatric diagnosis and BDNF on brain morphology measures
Regions of interest Psychiatric diagnosis N ¼ 289 Psychiatric diagnosis x genotype
interaction N ¼ 255
Df F P-value Partial g2 Df F P-value Partial g2
Hippocampus 1,281 4.807 0.029 0.017 1,242 0.305 0.581 0.001
Amygdala 1,281 3.453 0.064 0.012 1,242 1.166 0.281 0.005
Thickness caudal ACC 1,281 3.600 0.059 0.013 1,242 0.272 0.603 0.001
Thickness rostral ACC 1,281 14.559 0.000 0.049 1,242 3.852 0.051 0.016
SA caudal ACC 1,280 7.042 0.008 0.025 1,241 7.503 0.007 0.030
SA rostral ACC 1,280 1.995 0.159 0.007 1,241 0.222 0.638 0.001
Psychiatric diagnosis x expression
interaction N ¼ 195
Df F P-value Partial g2
Hippocampus 1,185 0.017 0.895 0.000
Amygdala 1,185 1.071 0.302 0.006
Thickness caudal ACC 1,185 2.164 0.143 0.012
Thickness rostral ACC 1,185 17.049 0.000 0.084
SA caudal ACC 1,184 0.892 0.346 0.005
SA rostral ACC 1,184 0.093 0.761 0.001
Psychiatric diagnosis x protein
interaction N ¼ 282
Df F P-value Partial g2
Hippocampus 1,272 0.735 0.392 0.003
Amygdala 1,272 0.003 0.954 0.000
Thickness caudal ACC 1,272 0.008 0.927 0.000
Thickness rostral ACC 1,272 0.249 0.618 0.001
SA caudal ACC 1,271 0.277 0.599 0.001
SA rostral ACC 1,271 0.285 0.594 0.001
Results of repeated measure ANOVA analyses. The dependent variables (hippocampal and amygdala volume, cortical thickness and surface area of the ACC) are shown
in the first column. Presented results are corrected for differences in age, sex, educational level, scan site and intracranial volume. ACC: anterior cingulate cortex; SA:
surface area.
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decrease cortical thickness. Reduced ACC volume and cortical
thickness have previously been reported in maltreated subjects
(Cohen et al., 2006; Treadway et al., 2009; Gerritsen et al., 2012;
Kelly et al., 2013), but results of our study suggest that this effect
may have been driven by subjects with a val/val genotype. As a
similar interaction effect between the presence of a psychiatric
diagnosis and BDNF was found on rostral ACC thickness, our
findings may be driven by or related to depression and/or anx-
iety disorders. It remains unclear why the effect of CM on
cortical thickness of the ACC was specifically observed in val-
allele homozygotes, as to our knowledge decreased BDNF
activity-dependent secretion and structural deficits have only
been found in met-carriers (e.g. Egan et al., 2003; Pezawas et al.,
2004; Montag et al., 2009). More research is needed to replicate
this effect and examine possible mechanisms.
In contrast to some, but not all, previous studies we did not
find evidence for structural changes in the hippocampus of mal-
treated subjects or a relationship between BDNF and hippocam-
pal volume. Although a CM*BDNF gene expression*hemisphere
interaction effect was observed (Table S1), post-hoc tests did
not reveal an effect of BDNF gene expression on the left or right
hippocampus in maltreated or non-maltreated subjects (data
not shown). Furthermore, we did not find a main effect of mal-
treatment on hippocampal volume. Several manual segmenta-
tion studies have shown decreased hippocampal volume in
individuals with a history of CM (Bremner et al., 1997; Weniger
et al., 2009)(with sample sizes of N¼ 34 and N¼ 42, respectively),
voxel-based morphometry studies in larger samples were not
able to replicate this finding (Van Harmelen et al., 2010;
Gerritsen et al., 2012) (N¼ 568 and N¼ 181), or only at trend-level
(Cohen et al., 2006) (N¼ 256), suggesting that the earlier results
may have been false positive results or may have been related
to differences in analysis technique (e.g. manual segmentation,
FreeSurfer segmentation or voxel-based morphometry) (Frodl
and O’Keane, 2013).
One of the strengths of the present study is that Val66Met
genotype, BDNF gene expression and protein serum levels were
determined in a large study sample, providing adequate power
to control for various potentially confounding variables. An ob-
vious limitation is that gene expression and protein levels were
determined in peripheral blood. However, preclinical studies
have shown that peripheral serum protein levels reflect cortical
and hippocampal BDNF (Karege et al., 2002; Sullivan et al., 2006;
Klein et al., 2011). A second limitation is that BDNF gene expres-
sion and Val66Met genotype information was not available
for every subject. Analyses revealed that subjects that could
not be included in the BDNF gene expression analyses, more
often had a diagnosis of depression and/or anxiety than individ-
uals that were not included (data not shown). Third, this
study was performed in a heterogeneous sample, consisting
of healthy controls and patients with major depression and/or
an anxiety disorders, however we corrected for the presence
of depression and/or anxiety in all CM analyses and
have also examined the effect of depression and/or anxiety
(in interaction with BDNF) on brain morphology to examine to
what extent our findings could also be explained by psychiatric
status.
In conclusion, CM is associated with lower amygdala vol-
ume, a region that has been implicated in many maltreatment-
related psychiatric disorders. Decreased amygdala volume may
underlie emotion regulation impairments. This finding of
smaller amygdala volume in maltreated individuals appears to
be even more pronounced in individuals carrying a met-allele,
while ACC thickness was specifically decreased in maltreated
val-homozygotes. The observed interaction effects are thus
complex, as childhood maltreatment has different effects on
brain morphology in met-carriers and val-homozoygotes.
Furthermore, the individual components of the BDNF pathway
did not show identical relationships with brain morphology.
These findings add to our understanding of the effect of early
life stress on the brain by showing that maltreatment-related
changes in brain structure are related to BDNF genotype and
gene expression, but not protein level. Further research is
needed to elucidate on potential causal mechanisms between
BDNF, CM and their effects on brain morphology, also in rela-
tion to vulnerability of developing a maltreatment-related psy-
chiatric disorder.
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